Navigation Links
Transgenomic Announces Partnership With Key Genomics for Ovarian Cancer Assay to Guide Therapeutic Options
Date:9/16/2008

Covers Development of Gene Expression Signatures Derived by COXEN Algorithm

as Molecular Test of Responsiveness to Current Treatments

OMAHA, Neb., and CHARLOTTESVILLE, Va., Sept. 16 /PRNewswire-FirstCall/ -- Transgenomic (OTC Bulletin Board: TBIO) today announced a partnership with Key Genomics to develop a molecular diagnostic test which will guide clinicians in their choice of currently available treatments for ovarian cancer. The new test will be powered by Key Genomics' predictive algorithm, COXEN ("CO-eXpression ExtrapolatioN").

Ovarian cancers are often diagnosed at the advanced stage of disease, after the tumor has spread beyond the ovary. Initial investigation of COXEN-derived genomic signatures in clinical trials has demonstrated that the test can distinguish responders from patients who do not benefit from a therapy. "Getting the patient the best therapeutic option as quickly as possible is a key factor in survival," commented Craig Tuttle, CEO of Transgenomic. "Using this approach, we believe physicians will be able to quickly direct ovarian cancer patients towards appropriate lines of therapy."

Epithelial carcinoma of the ovary is one of the most common gynecologic malignancies and the fifth most frequent cause of cancer death in women. In 2008, ovarian cancer will be diagnosed in more than 20,000 women in the United States.(1) Approximately 15,000 women will die from the disease. In the U.S., we spend an estimated $2.2 billion per year to treat ovarian cancer.

The Companies plan to work collaboratively with the goal of improving patient outcomes through personalized medicine. Transgenomics' highly sensitive technologies for DNA mutation detection and analysis are expected to complement and enhance COXEN, which combines genomic and pharmacological response data on a set of widely used cancer cell lines to generate molecular signatures of patient response to specific anti-cancer agents.(2) This innovative test is
'/>"/>

SOURCE Transgenomic
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Transgenomic Reports Second Quarter 2008 Results
2. Reminder: Webcast Alert: Transgenomic Inc. Announces Second Quarter 2008 Earnings Release Conference Call Webcast
3. Webcast Alert: Transgenomic Inc. Announces Second Quarter 2008 Earnings Release Conference Call Webcast
4. Transgenomic Introduces SURVEYOR(R) Endonuclease Adaptor-Ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation
5. Webcast Alert: Transgenomic Inc. Announces First Quarter 2008 Earnings Release Conference Call Webcast
6. Transgenomic Opens Pharmacogenomics Laboratory in China
7. Reminder Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2007 Earnings Release Conference Call Webcast
8. Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2007 Earnings Release Conference Call Webcast
9. Transgenomic Appoints David Pauluzzi to Board of Directors
10. Transgenomic, Inc. Forms Scientific Advisory Board
11. Webcast Alert: Transgenomic Inc. Announces Third Quarter 2007 Earnings Release Conference Call Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... and Hershey, PA (PRWEB) December 19, 2014 ... BJCT), a leading developer and manufacturer of needle-free ... into an agreement with Immunomic Therapeutics, Inc. (“ITI”) ... needle-free injection device with its LAMP™ vaccine platform. ... option for an exclusive Worldwide license to the ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one of the nation’s ... Pharm.D. to the newly created position of Vice President ... Dr. Maroulis will continue to manage the entire specialty ... pharmacies as the company expands. Dr. Maroulis has been ... has served in many different capacities in the pharmacy, ...
(Date:12/19/2014)... PLEASANTON, Calif. , Dec. 19, 2014  Roche ... acquisition of Bina Technologies, Inc. (Bina), a privately ... California , USA. Bina provides a big ... next generation sequencing (NGS) data. Bina,s proprietary on-market ... translational and academic researchers to perform fast and ...
(Date:12/19/2014)... Dec. 19, 2014 Decision Resources Group finds ... at a 12 percent compound annual growth rate through ... aging population and the increasing adoption of dental implants. ... will also spur demand for dental biomaterials because ... and periodontal treatments. Other key findings from ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3
... a,specialist in antibiotics development, announces that Dr. George ... the Company., Dr. Golumbeski brings to the ... recently as Vice President of Business Development,Licensing & ... In this,position he was responsible for the full ...
... July 2 /Xinhua-PRNewswire-FirstCall/,-- China Pharma Holdings, Inc. (,China ... markets generic and branded bio-,pharmaceutical products in China, ... Collins Stewart Fourth Annual Growth Conference on Tuesday,July ... being held at the Mandarin,Oriental Hotel in New ...
... new therapies based on cells manufactured from ... provide funding round, SALT LAKE CITY and HAMBURG, ... the forefront of innovative cell therapies,for the treatment of ... Series A financing. The round was led by SV ...
Cached Biology Technology:Nabriva Therapeutics Announces Appointment of New CEO 2China Pharma Holdings, Inc. to Present at Collins Stewart Fourth Annual Growth Conference in New York on July 8, 2008 at 2:00 p.m. EDT 2AlloCure Inc. Closes $14.5MM Series A Round to Develop a Stem Cell Therapy for Acute Kidney Injury 2AlloCure Inc. Closes $14.5MM Series A Round to Develop a Stem Cell Therapy for Acute Kidney Injury 3
(Date:11/21/2014)... 2014 According to a new ... (Video, RFID, Access Control, Intrusion Detection, Parking Management, Under ... Component Service Geography - Global Forecasts to 2020", published ... to be around $25 Billion in 2014 and is ... a CAGR of 8.69%. Browse 116 market ...
(Date:11/21/2014)... Nov. 20, 2014 C-Labs LLC, a leading ... of Things (IoT), today announced the appointment of ... officer. Previously a strategic advisor to the firm, Mr. ... Mr. Traynor is based out of the C-Labs office ... to Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... Nov. 17, 2014   News ... collaborate to develop The Partners Data Lake, an ... Partners Data Lake will allow researcher and clinicians ... treatment and the lives of patients , ... clinical activities across the Partners system, breaking down ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... Citrus species are among the most important fruit trees in ... thought to be more than 4,000 years. Until now, however, ... orange ( Citrus sinensis ), lemon ( C. limon ), ... A team of researchers from China has published a study ...
... CAMutant presenilin is infamous for its role in the ... strike people as early as their 30s. In their ... productive side: It helps embryonic motor neurons navigate the ... them in on their way to their proper targets. ...
... 18, 2011 Using chemical compounds found in a Japanese ... light, a Scripps Research Institute team has created a unique ... potential. Already, one of the compounds has shown great promise ... With the report of their work scheduled to appear ...
Cached Biology News:Genetic origin of cultivated citrus determined 2Unlocking the secret(ase) of building neural circuits 2Unlocking the secret(ase) of building neural circuits 3Scripps Research team creates new synthetic compound with HIV-fighting promise 2Scripps Research team creates new synthetic compound with HIV-fighting promise 3
... cooling coil, Trans-Blot cell, provides ... high-intensity, and extended electrophoretic transfer ... Trans-Blot cell. Use of the ... to an external water recirculator, ...
... of next-generation features into a small-footprint design, ... flexible laboratory solutions. It puts every aspect ... dispensing, and integrations into a single, ... as it is efficient and economical. The ...
... Biomek FX P is the latest entry ... for greater positional accuracy and increased robustness, it ... application. It can be configured with either one ... capacity, the Biomek FX P sets the ...
These Costar 96-well, flat-bottom polystyrene EIA plates are used for EIAs, ELISAs, and other protein binding assays. Supplied as box of 100 (20 packages; 5 plates per package)....
Biology Products: